• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

    3/14/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024.

    Fourth Quarter 2024 Financial Highlights

    • Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.
    • Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.
    • U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period of 2023.
    • Non-GAAP net income[1] was RMB251.5 million (US$34.5 million) in the fourth quarter of 2024, compared with RMB432.6 million in the same period of 2023.

    Fiscal Year 2024 Financial Highlights

    • Net revenues were RMB2,748.6 million (US$376.6 million) in fiscal year 2024, compared with RMB 1,586.4 million in the prior year.
    • Gross margin was 26.4% in fiscal year 2024, compared with 24.4% in the prior year.
    • U.S. GAAP net income was RMB564.3 million (US$77.3 million) in fiscal year 2024, compared with RMB541.0 million in the prior year.
    • Non-GAAP net income was RMB934.0 million (US$128.0 million) in fiscal year 2024, compared with RMB903.9 million in the prior year.

    "2024 was a remarkable year for RLX, highlighted by tremendous progress in our global operations," commented Ms. Ying (Kate) Wang, Co-founder, Chairperson of the Board of Directors, and Chief Executive Officer of RLX Technology. "We've holistically upgraded our organizational framework and refined our business models to address international markets' diverse and dynamic needs, driving significant growth and solidifying our market leadership in multiple regions. The innovative open-system and disposable e-vapor products we introduced in 2024 set new trends across the international markets, reaffirming our dedication to advancing harm-reduction solutions. Moving into 2025, we will prioritize innovation, compliance, and diversity in our product portfolio while navigating the industry dynamics to capture new opportunities and drive long-term success."

    Mr. Chao Lu, Chief Financial Officer of RLX Technology, added, "Our focus on global expansion throughout 2024 fueled an impressive year-over-year increase in full-year revenue to RMB 2.7 billion, up 73.3%. Notably, in the fourth quarter alone, we achieved a non-GAAP operating profit of RMB112.6 million, marking a sequential rise for the fourth consecutive quarter and culminating in a significant return to profitability for the full year 2024. Furthermore, we continued to return value to our shareholders through our share repurchase program and cash dividends. Looking ahead, we will continue to pursue sustainable, profitable growth and enhanced shareholder returns through ongoing innovation and strong strategic execution."

    Fourth Quarter 2024 Financial Results

    Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023. The increase was primarily due to our international expansion.

    Gross profit was RMB219.9 million (US$30.1 million) in the fourth quarter of 2024, compared with RMB123.4 million in the same period of 2023.

    Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023. The increase was primarily due to a favorable change in the revenue mix and cost optimization initiatives.

    Operating expenses were RMB231.5 million (US$31.7 million) in the fourth quarter of 2024, compared with RMB263.9 million in the same period of 2023. The decrease was primarily due to the fluctuation of share-based compensation expenses, offset by the increase in salaries and welfare expenses. The changes in share-based compensation expenses were primarily due to the changes in the fair value of the share incentive awards that the Company granted to its employees in line with the fluctuations in the Company's share price.

    Selling expenses were RMB45.4 million (US$6.2 million) in the fourth quarter of 2024, compared with RMB38.0 million in the same period of 2023, primarily due to an increase in salaries, welfare benefits and branding expenses.

    General and administrative expenses were RMB153.7 million (US$21.1 million) in the fourth quarter of 2024, compared with RMB204.0 million in the same period of 2023, primarily due to a decrease in share-based compensation expenses as well as in legal and other consulting fees, slightly offset by an increase in salaries and welfare expenses.

    Research and development expenses were RMB32.4 million (US$4.4 million) in the fourth quarter of 2024, compared with RMB21.9 million in the same period of 2023, primarily due to an increase in salaries and welfare expenses, slightly offset by a decrease in share-based compensation expenses.

    Loss from operations was RMB11.5 million (US$1.6 million) in the fourth quarter of 2024, compared with loss from operations of RMB140.5 million in the same period of 2023.

    Income tax expense was RMB26.3 million (US$3.6 million) in the fourth quarter of 2024, compared with RMB15.1 million in the same period of 2023.

    U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period of 2023.

    Non-GAAP net income was RMB251.5 million (US$34.5 million) in the fourth quarter of 2024, compared with RMB432.6 million in the same period of 2023.

    U.S. GAAP basic and diluted net income per American depositary share ("ADS") were RMB0.100 (US$0.014) and RMB0.094 (US$0.013), respectively, in the fourth quarter of 2024, compared with U.S. GAAP basic and diluted net income per ADS of RMB0.166 and RMB0.161, respectively, in the same period of 2023.

    Non-GAAP basic and diluted net income per ADS[2] were RMB0.201 (US$0.028) and RMB0.190 (US$0.026), respectively, in the fourth quarter of 2024, compared with non-GAAP basic and diluted net income per ADS of RMB0.335 and RMB0.325, respectively, in the same period of 2023.

    Balance Sheet and Cash Flow

    As of December 31, 2024, the Company had cash and cash equivalents, restricted cash, short-term bank deposits, net, short-term investments, net, long-term bank deposits, net and long-term investment securities, net of RMB15,870.8 million (US$2,174.3 million), compared with RMB15,361.7 million as of September 30, 2024. In the fourth quarter of 2024, net cash generated from operating activities was RMB497.0 million (US$68.1 million).

    Fiscal Year 2024 Financial Results

    Net revenues were RMB2,748.6 million (US$376.6 million) in fiscal year 2024, compared with RMB1,586.4 million in the prior year. The increase was primarily due to our international expansion.

    Gross profit was RMB726.5 million (US$99.5 million) in fiscal year 2024, compared with RMB387.7 million in the prior year.

    Gross margin increased to 26.4% in fiscal year 2024 from 24.4% in the prior year, primarily due to a favorable change in the revenue mix and cost optimization initiatives.

    Operating expenses were RMB833.7 million (US$114.2 million) in fiscal year 2024, representing a decrease of 5.7% from RMB884.4 million in the prior year. The decrease in operating expenses was primarily due to the decrease in salaries and welfare benefits.

    Selling expenses increased by 7.4% to RMB229.5 million (US$31.4 million) in fiscal year 2024 from RMB 213.7 million in the prior year, mainly driven by the increase in branding expenses and share-based compensation expenses, offset by a decrease in salaries and welfare expenses.

    General and administrative expenses increased by 3.6% to RMB515.9 million (US$70.7 million) in fiscal year 2024 from RMB498.0 million in the prior year, primarily attributable to the increase in share-based compensation expenses and software and technical service expenses, slightly offset by a decrease in legal and consulting expenses as well as in depreciation and amortization expenses.

    Research and development expenses decreased by 48.9% to RMB88.3 million (US$12.1 million) in fiscal year 2024 from RMB172.7 million in the prior year, mainly driven by the decrease in share-based compensation expenses and salaries and welfare benefits.

    Loss from operations was RMB107.1 million (US$14.7 million) in fiscal year 2024, compared with RMB 496.7 million in the prior year.

    Income tax expense was RMB94.5 million (US$12.9 million) in fiscal year 2024, representing an increase of 86.1% from RMB50.8 million in the prior year.

    U.S. GAAP net income was RMB564.3 million (US$77.3 million) in fiscal year 2024, compared with RMB541.0 million in the prior year.

    Non-GAAP net income was RMB934.0 million (US$128.0 million) in fiscal year 2024, compared with RMB903.9 million in the prior year.

    U.S. GAAP basic and diluted net income per ADS were RMB0.448 (US$0.061) and RMB0.428 (US$0.059), respectively, in fiscal year 2024, compared with U.S. GAAP basic and diluted net income per ADS of RMB0.407 and RMB0.399, respectively, in the prior year.

    Non-GAAP basic and diluted net income per ADS were RMB0.748 (US$0.102) and RMB0.715 (US$0.098), respectively, in fiscal year 2024, compared with non-GAAP basic and diluted net income per ADS of RMB0.684 and RMB0.669, respectively, in the prior year.

    Share Repurchase Program and Dividend Payment

    The Company repurchased approximately US$109.2 million of its ordinary shares represented by ADSs during fiscal year 2024. As of December 31, 2024, the Company had cumulatively repurchased US$304.7 million of its ordinary shares represented by ADSs.

    By repurchasing shares throughout 2024 and declaring cash dividends in November 2024, the Company returned approximately US$122.9 million to its shareholders during fiscal year 2024.

    Conference Call

    The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 14, 2025 (8:00 PM Beijing/Hong Kong Time on March 14, 2025).

    Dial-in details for the earnings conference call are as follows:

    United States (toll-free):

    +1-888-317-6003

    International:

    +1-412-317-6061

    Hong Kong, China (toll-free):

    +800-963-976

    Hong Kong, China:

    +852-5808-1995

    Mainland China:

    400-120-6115

    Participant Code:

    7971219

    Participants should dial in 10 minutes before the scheduled start time and ask to be connected to the call for "RLX Technology Inc." with the Participant Code as set forth above.

    Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.relxtech.com.

    A replay of the conference call will be accessible approximately two hours after the conclusion of the call until March 21, 2025, by dialing the following telephone numbers:

    United States:

    +1-877-344-7529

    International:

    +1-412-317-0088

    Replay Access Code:

    5229492

    [1] Non-GAAP net income is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    [2] Non-GAAP basic and diluted net income per ADS is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    About RLX Technology Inc.

    RLX Technology Inc. (NYSE:RLX) is a leading global branded e-vapor company. The Company leverages its strong in-house technology, product development capabilities and in-depth insights into adult smokers' needs to develop superior e-vapor products.

    For more information, please visit: http://ir.relxtech.com.

    Non-GAAP Financial Measures

    The Company uses non-GAAP net income, non-GAAP operating profit and non-GAAP basic and diluted net income per ADS, each a non-GAAP financial measure, in evaluating its operating results and for financial and operational decision-making purposes. Non-GAAP net income represents net income excluding share-based compensation expenses. Non-GAAP basic and diluted net income per ADS is computed using non-GAAP net income attributable to RLX Technology Inc. and the same number of ADSs used in U.S. GAAP basic and diluted net income per ADS calculation.

    The Company presents these non-GAAP financial measures because they are used by the management to evaluate its operating performance and formulate business plans. The Company believes that they help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that are included in net income. The Company also believes that the use of the non-GAAP measures facilitates investors' assessment of its operating performance, as they could provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by the management in its financial and operational decision making.

    The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. They should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per ADS or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review its historical non-GAAP financial measures to the most directly comparable U.S. GAAP measures. The non-GAAP financial measures here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. The Company encourages investors and others to review its financial information in its entirety and not rely on any single financial measure.

    For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliation of GAAP and non-GAAP Results" set forth at the end of this press release.

    Exchange Rate Information

    This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.2993 to US$1.00, the exchange rate on December 31, 2024, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and similar statements. Among other things, quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; trends and competition in the global e-vapor market; changes in its revenues and certain cost or expense items; governmental policies, laws and regulations across various jurisdictions relating to the Company's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

    For more information, please contact:

    In China:

    RLX Technology Inc.

    Head of Capital Markets

    Sam Tsang

    Email: [email protected] 

    Piacente Financial Communications

    Jenny Cai

    Tel: +86-10-6508-0677

    Email: [email protected] 

    In the United States:

    Piacente Financial Communications

    Brandi Piacente

    Tel: +1-212-481-2050

    Email: [email protected] 

     

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (All amounts in thousands)











    As of



    December 31,

    December 31,

    December 31,



    2023

    2024

    2024



    RMB

    RMB

    US$

    ASSETS







    Current assets:







    Cash and cash equivalents

    2,390,298

    5,593,492

    766,305

    Restricted cash

    29,760

    50,867

    6,969

    Short-term bank deposits, net

    2,631,256

    2,179,886

    298,643

    Receivables from online payment platforms

    6,893

    4,722

    647

    Short-term investments, net

    3,093,133

    719,755

    98,606

    Accounts and notes receivable, net

    60,482

    78,484

    10,752

    Inventories

    144,850

    142,552

    19,530

    Amounts due from related parties

    118,736

    346,132

    47,420

    Prepayments and other current assets, net

    508,435

    185,091

    25,357

    Total current assets

    8,983,843

    9,300,981

    1,274,229

    Non-current assets:







    Property, equipment and leasehold improvement, net

    77,358

    50,787

    6,958

    Intangible assets, net

    69,778

    52,796

    7,233

    Long-term investments, net

    8,000

    8,000

    1,096

    Deferred tax assets, net

    58,263

    38,067

    5,215

    Right-of-use assets, net

    52,562

    24,110

    3,303

    Long-term bank deposits, net

    1,757,804

    727,448

    99,660

    Long-term investment securities, net

    5,236,109

    6,599,365

    904,109

    Goodwill

    66,506

    59,581

    8,163

    Other non-current assets, net

    4,874

    9,914

    1,358

    Total non-current assets

    7,331,254

    7,570,068

    1,037,095

    Total assets

    16,315,097

    16,871,049

    2,311,324









    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts and notes payable

    266,426

    458,538

    62,819

    Contract liabilities

    49,586

    10,610

    1,454

    Salary and welfare benefits payable

    39,256

    73,740

    10,102

    Taxes payable

    77,164

    126,154

    17,283

    Short-term loan

    -

    40,000

    5,480

    Accrued expenses and other current liabilities

    103,996

    108,816

    14,908

    Amounts due to related parties

    101,927

    27,401

    3,754

    Dividend payable

    881

    1,144

    157

    Lease liabilities - current portion

    29,435

    11,447

    1,568

    Total current liabilities

    668,671

    857,850

    117,525









    Non-current liabilities:







    Deferred tax liabilities

    23,591

    16,196

    2,219

    Lease liabilities - non-current portion

    24,419

    7,050

    966

    Total non-current liabilities

    48,010

    23,246

    3,185

    Total liabilities

    716,681

    881,096

    120,710

















    Shareholders' Equity:







    Total RLX Technology Inc. shareholders' equity

    15,609,393

    15,988,216

    2,190,376

    Noncontrolling interests

    (10,977)

    1,737

    238

    Total shareholders' equity

    15,598,416

    15,989,953

    2,190,614









    Total liabilities and shareholders' equity

    16,315,097

    16,871,049

    2,311,324

     

     

    RLX TECHNOLOGY INC.  

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

    COMPREHENSIVE INCOME/(LOSS)

    (All amounts in thousands, except for number of shares and per share data, or otherwise noted)





















    For the three months ended



    For the year ended



    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,



    2023

    2024

    2024

    2024



    2023

    2024

    2024



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



















    Net revenues

    520,468

    756,288

    813,489

    111,448



    1,586,397

    2,748,576

    376,553

    Cost of revenues

    (327,325)

    (473,379)

    (516,305)

    (70,733)



    (856,329)

    (1,718,006)

    (235,366)

    Excise tax on products

    (69,730)

    (76,933)

    (77,278)

    (10,587)



    (342,354)

    (304,053)

    (41,655)

    Gross profit

    123,413

    205,976

    219,906

    30,128



    387,714

    726,517

    99,532



















    Operating expenses:

















    Selling expenses

    (37,985)

    (68,975)

    (45,369)

    (6,216)



    (213,723)

    (229,466)

    (31,437)

    General and administrative expenses

    (204,030)

    (123,226)

    (153,710)

    (21,058)



    (498,015)

    (515,887)

    (70,676)

    Research and development expenses

    (21,904)

    (24,435)

    (32,374)

    (4,435)



    (172,686)

    (88,309)

    (12,098)

    Total operating expenses

    (263,919)

    (216,636)

    (231,453)

    (31,709)



    (884,424)

    (833,662)

    (114,211)



















    Loss from operations

    (140,506)

    (10,660)

    (11,547)

    (1,581)



    (496,710)

    (107,145)

    (14,679)



















    Other income:

















    Interest income, net

    157,928

    156,659

    146,664

    20,093



    627,879

    616,388

    84,445

    Investment income  

    182,699

    13,070

    11,072

    1,517



    245,700

    49,636

    6,800

    Others, net

    30,925

    40,745

    7,497

    1,027



    214,874

    99,924

    13,690

    Income before income tax

    231,046

    199,814

    153,686

    21,056



    591,743

    658,803

    90,256

    Income tax expense  

    (15,078)

    (30,423)

    (26,303)

    (3,604)



    (50,755)

    (94,459)

    (12,941)

    Net Income

    215,968

    169,391

    127,383

    17,452



    540,988

    564,344

    77,315

    Less: net income attributable to noncontrolling

        interests

    2,491

    3,737

    5,422

    743



    6,660

    12,507

    1,713

    Net income attributable to RLX Technology Inc.

    213,477

    165,654

    121,961

    16,709



    534,328

    551,837

    75,602

    Other comprehensive (loss)/income:

















    Foreign currency translation adjustments

    (132,470)

    (181,148)

    268,079

    36,727



    198,534

    143,811

    19,702

    Unrealized (loss)/income on long-term investment

        securities

    (11,288)

    5,292

    (8,151)

    (1,117)



    632

    (2,167)

    (297)

    Total other comprehensive (loss)/income

    (143,758)

    (175,856)

    259,928

    35,610



    199,166

    141,644

    19,405

    Total comprehensive income/(loss)

    72,210

    (6,465)

    387,311

    53,062



    740,154

    705,988

    96,720

    Less: total comprehensive income attributable to

        noncontrolling interests

    2,491

    3,730

    5,442

    745



    6,660

    12,520

    1,713

    Total comprehensive income/(loss) attributable to

        RLX Technology Inc.

    69,719

    (10,195)

    381,869

    52,317



    733,494

    693,468

    95,007



















    Net income per ordinary share/ADS 

















     Basic

    0.166

    0.135

    0.100

    0.014



    0.407

    0.448

    0.061

     Diluted

    0.161

    0.129

    0.094

    0.013



    0.399

    0.428

    0.059



















    Weighted average number of ordinary shares/ADSs

















    Basic

    1,285,752,182

    1,225,417,517

    1,225,140,420

    1,225,140,420



    1,311,401,901

    1,232,148,531

    1,232,148,531

    Diluted

    1,324,466,240

    1,287,927,444

    1,291,925,422

    1,291,925,422



    1,340,445,653

    1,288,911,783

    1,288,911,783

     

     

    RLX TECHNOLOGY INC.

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

    (All amounts in thousands, except for number of shares and per share data)













    For the three months ended



    For the year ended



    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,



    2023

    2024

    2024

    2024



    2023

    2024

    2024



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$

    Net income

    215,968

    169,391

    127,383

    17,452



    540,988

    564,344

    77,315

    Add: share-based compensation expenses

















           Selling expenses

    12,128

    5,768

    13,020

    1,784



    16,700

    32,563

    4,461

           General and administrative expenses

    194,153

    85,295

    103,894

    14,233



    334,344

    348,629

    47,762

           Research and development expenses

    10,335

    1,446

    7,210

    988



    11,824

    (11,537)

    (1,581)

    Non-GAAP net income

    432,584

    261,900

    251,507

    34,457



    903,856

    933,999

    127,957



















    Net income attributable to RLX Technology Inc.

    213,477

    165,654

    121,961

    16,709



    534,328

    551,837

    75,602

    Add: share-based compensation expenses

    216,616

    92,509

    124,124

    17,005



    362,868

    369,655

    50,642

    Non-GAAP net income attributable to RLX

        Technology Inc.

    430,093

    258,163

    246,085

    33,714



    897,196

    921,492

    126,244



















    Non-GAAP net income per ordinary share/ADS

















    - Basic

    0.335

    0.211

    0.201

    0.028



    0.684

    0.748

    0.102

    - Diluted

    0.325

    0.200

    0.190

    0.026



    0.669

    0.715

    0.098

    Weighted average number of ordinary

    shares/ADSs

















    - Basic

    1,285,752,182

    1,225,417,517

    1,225,140,420

    1,225,140,420



    1,311,401,901

    1,232,148,531

    1,232,148,531

    - Diluted

    1,324,466,240

    1,287,927,444

    1,291,925,422

    1,291,925,422



    1,340,445,653

    1,288,911,783

    1,288,911,783

     

     

    RLX TECHNOLOGY INC.



    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



    (All amounts in thousands)

























    For the three months ended



    For the year ended





    December 31,

    September 30,

    December 31,

    December 31,



    December 31,

    December 31,

    December 31,





    2023

    2024

    2024

    2024



    2023

    2024

    2024





    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



    Net cash generated from operating activities

    305,197

    156,554

    497,011

    68,090



    198,703

    854,349

    117,045



    Net cash generated from investing activities

    310,274

    139,120

    1,901,084

    260,447



    2,091,145

    3,018,001

    413,464



    Net cash used in financing activities

    (791,905)

    (74,780)

    (130,366)

    (17,860)



    (1,193,216)

    (678,031)

    (92,890)



    Effect of foreign exchange rate changes on cash, cash

        equivalents and restricted cash

    (18,544)

    (45,818)

    62,865

    8,613



    34,340

    29,982

    4,108



    Net (decrease)/increase in cash and cash equivalents

        and restricted cash

    (194,978)

    175,076

    2,330,594

    319,290



    1,130,972

    3,224,301

    441,727



    Cash, cash equivalents and restricted cash at the

        beginning of the period

    2,615,036

    3,138,689

    3,313,765

    453,984



    1,289,086

    2,420,058

    331,547



    Cash, cash equivalents and restricted cash at the

        end of the period

    2,420,058

    3,313,765

    5,644,359

    773,274



    2,420,058

    5,644,359

    773,274























     

    Cision View original content:https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-fourth-quarter-and-fiscal-year-2024-financial-results-302401678.html

    SOURCE RLX Technology Inc.

    Get the next $RLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    SEC Filings

    See more
    • SEC Form 20-F filed by RLX Technology Inc.

      20-F - RLX Technology Inc. (0001828365) (Filer)

      4/17/25 4:01:47 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      3/14/25 6:10:16 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      11/15/24 4:01:25 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/7/24 6:06:29 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/6/24 4:01:28 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/14/23 6:01:42 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Files 2024 Annual Report on Form 20-F

      SHENZHEN, China, April 17, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC") on April 17, 2025. The annual report on Form 20-F can be accessed on the SEC's website at https://www.sec.gov and on the Company's investor relations website at https://ir.relxtech.com. The Company will provide a hard copy of its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. About RLX Technology Inc. RLX Techno

      4/17/25 8:00:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Financials

    Live finance-specific insights

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 14, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on March 14, 2025 - SHENZHEN, China, March 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before the U.S. markets open on Friday, March 14, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 14, 2025 (8:00 PM Beijing/Hong Kong Time on March 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412

      3/3/25 10:30:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RLX Technology downgraded by Citigroup with a new price target

      Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

      3/17/25 7:42:34 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • UBS initiated coverage on RLX Technology with a new price target

      UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

      8/8/23 9:12:45 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care